Preparation, characterization, and biological analysis of liposomal formulations of vincristine

Methods in Enzymology

Volumn 391, Issue SPEC. ISS., 2005, Pages 40-57

  Waterhouse, Dawn N ^a   Madden, Thomas D ^a   Cullis, Pieter R ^a   Bally, Marcel B ^a   Mayer, Lawrence D ^a   Webb, Murray S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMYCIN; CHOLESTEROL; DILAUROYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLETHANOLAMINE; DIOLEOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; DIPALMITOYLPHOSPHATIDYLSERINE; DISTEAROYLPHOSPHATIDIC ACID; DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; EGG PHOSPHATIDYLCHOLINE; ETHANOLAMINE DERIVATIVE; GANGLIOSIDE GM1; IONOPHORE; LIPOSOME; MACROGOL; N PALMITOYLSPHINGOSINE; NIGERICIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; SPHINGOMYELIN; SPHINGOSINE DERIVATIVE; SURAMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ANTINEOPLASTIC ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; EVAPORATION; FREEZE DRYING; HUMAN; LIPID COMPOSITION; LIPID MEMBRANE; METHODOLOGY; NONHUMAN; PARTICLE SIZE; PH; PHASE TRANSITION; PLASMA HALF LIFE; PRIORITY JOURNAL; REVIEW; SURFACE CHARGE;

CATHARANTHUS;

EID: 13844275425     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(05)91002-1     Document Type: Article

References (38)

1. Allen T.M., Everest J.M. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J. Pharmacol. Exp. Ther. 226:1983;539-544
2. Allen T.M., Hansen C., Rutledge J. Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta. 981:1989;27-35
3. Bally M.B., Lim H., Cullis P.R., Mayer L.D. Controlling the drug delivery attributes of lipid-based drug formulations. J. Liposome Res. 8:1998;299-335
4. Boman N.L., Mayer L.D., Cullis P.R. Optimization of the retention properties of vincristine in liposomal systems. Biochim. Biophys. Acta. 1152:1993;253-258
5. Boman N.L., Masin D., Mayer L.D., Cullis P.R., Bally M.B. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 54:1994;2830-2833
6. Boman N.L., Bally M.B., Cullis P.R., Mayer L.D., Webb M.S. Encapsulation of vincristine in liposomes reduces its toxicity and improves its antitumor efficacy. J. Liposome Res. 5:1995;523-541
7. Boman N.L., Cullis P.R., Mayer L.D., Bally M.B., Webb M.S. Liposomal vincristine: The central role of drug retention in defining therapeutically optimized anticancer formulations. Woodle M.C., Storm G. "Long Circulating Liposomes: Old Drugs, New Therapeutics" 1997;29 Landes Bioscience, Georgetown, TX
8. Budavari S., O'Neil M.J., Smith A. "The Merck Index." 1989;Merck & Co., Inc., Rahway, NJ
9. Fenske D.B., Wong K.F., Maurer E., Maurer N., Leenhouts J.M., Boman N., Amankwa L., Cullis P.R. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim. Biophys. Acta. 1414:1998;188-204
10. Fiske C.H., Subbarow Y. The colorimetric determination of phosphorus. J. Biol. Chem. 66:1925;375-400
11. Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA. 85:1988;6949-6953
12. Harrigan P.R., Hope M.J., Redelmeier T.E., Cullis P.R. Determination of transmembrane pH gradients and membrane potentials in liposomes. Biophys. J. 63:1992;1336-1345
13. Hope M.J., Bally M.B., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure: Characterization of size, trapped volume, and ability to maintain a membrane potential. Biochim. Biophys. Acta. 812:1985;55-65
14. Jackson D.V. Jr., Paschold E.H., Spurr C.L., Muss H.B., Richards F. II, Cooper M.R., White D.R., Stuart J.J., Hopkins J.O., Rich R. Jr., Wells H.B. Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion. Cancer. 53:1984;2601-2606
15. Jackson D.V. Jr., Sethi V.S., Pharm M., Spurr C.L., Willard V., White D.R., Richards F., Stuart J.J., Muss H.B., Cooper M.R., Homesley H.D., Jobson V.W., Castle M.C. Intravenous vincristine infusion: Phase I trial. Cancer. 48:1981;2559-2564
16. Johnstone S.A., Masin D., Mayer L., Bally M.B. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim. Biophys. Acta. 1513:2001;25-37
17. Kirby C., Clarke J., Gregoriadis G. Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum. FEBS Lett. 111:1980;324-327
18. Krishna R., Webb M.S., St.-Onge G., Mayer L.D. Liposomal and non-liposomal drug pharmacokinetics after administration of liposome- encapsulated vincristine and their contribution to drug tissue distribution properties. J. Pharmacol. Exp. Ther. 298:2001;1206-1212
19. Leo A., Hansch C., Elkins D. Partition coefficients and their uses. Chem. Rev. 71:1971;525-616
20. Mayer L.D., St.-Onge G. Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Anal. Biochem. 232:1995;149-157
21. Mayer L.D., Gelmon K., Cullis P.R., Boman N., Webb M.S., Embree L., Tolcher T., Bally M.B. Preclinical and clinical studies with liposomal vincristine. Hirota S. "Progress in Drug Delivery Systems IV" 1995;151 Biomedical Research Foundation, Tokyo
22. Mayer L.D., Hope M.J., Cullis P.R., Janoff A.S. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim. Biophys. Acta. 817:1985;193-196
23. Mayer L.D., Madden T.D., Bally M.B., Cullis P.R. Preparation of streptavidin liposomes for use in ligand specific targeting applications. Gregoriadis G. "Liposome Technology, Volume II. Entrapment of Drugs and Other Materials" 1993;27 CRC Press, Boca Raton, FL
24. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA. 88:1991;11460-11464
25. Rottenberg H., Grunwald T., Avron M. Determination of pH in chloroplasts. I. Distribution of (14 C) methylamine. Eur. J. Biochem. 25:1972;54-63
26. Rowinsky E.K., Donehower R.C. Non-small cell lung cancer. DeVita V.T. Jr., Hellman S., Rosenberg S.A. "Cancer. Principles and Practices of Oncology" 1997;467 Lippincott-Raven, Philadelphia
27. Sarris A.H., Hagemeister F., Romaguera J., Rodriguez M.A., McLaughlin P., Tsimberidou A.M., Medeiros L.J., Samuels B., Pate O., Oholendt M., Kantarjian H., Burge C., Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial. Ann. Oncol. 11:2000;69-72
28. Sarris A.H., Romaguera J., Hagemeister F., Rodriguez M.A., McLaughlin P., Dang N., Tsimberidou A.M., Medeiros L.J., Samuels B., Oholendt M., Pate O., Burge C., Cabanillas F. Liposomal vincristine: A phase II trial in relapsed or refractory non-Hodgkin's lymphoma (NHL). American Society of Hematology 41st Annual Meeting. 1999;. Abstract #412
29. Scherphof G., Roerdink F., Waite M., Parks J. Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim. Biophys. Acta. 542:1978;296-307
30. Senior J., Gregoriadis G. Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett. 145:1982;109-114
31. Senior J., Gregoriadis G., Mitropoulos K.A. Stability and clearance of small unilamellar liposomes. Studies with normal and lipoprotein-deficient mice. Biochim. Biophys. Acta. 760:1983;111-118
32. Shipp M.A., Mauch P.M., Harris N.L. Non-Hodgkin's lymphomas. DeVita V.T. Jr., Hellman S., Rosenberg S.A. "Cancer. Principles and Practices of Oncology" 1997;2165 Lippincott-Raven, Philadelphia
33. Svoboda G.H. Alkaloids of Vinca rosea. IX. Extraction and characterization of leurosidine and leurocristine. Lloydia. 24:1961;173-178
34. Tardi P.G., Boman N.L., Cullis P.R. Liposomal doxorubicin. J. Drug Target. 4:1996;129-140
35. Webb M.S., Harasym T.O., Masin D., Bally M.B., Mayer L.D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer. 72:1995a;896-904
36. Webb M.S., Wheeler J.J., Bally M.B., Mayer L.D. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: Implications for drug delivery. Biochim. Biophys. Acta. 1238:1995b;147-155
37. Webb M.S., Logan P., Kanter P.M., St-Onge G., Gelmon K., Harasym T., Mayer L.D., Bally M.B. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother. Pharmacol. 42:1998;461-470
38. Zhu G., Oto E., Vaage J., Quinn Y., Newman M., Engbers C., Uster P. The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity. Cancer Chemother. Pharmacol. 39:1996;138-142